Table 1.
Characteristics of patients with UR-LAPC who underwent gemcitabine plus nab-paclitaxel as first-line chemotherapy.
| All | CRT Group | CTx Group | p-Value | |
|---|---|---|---|---|
| (n = 45) | (n = 25) | (n = 20) | ||
| Age (years) * | 68 (48–82) | 67 (48–82) | 68 (48–76) | 0.514 |
| Sex (male/female) | 24/21 | 11/14 | 10/10 | 0.769 |
| ECOG PS (0/1) | 33/12 | 17/8 | 16/4 | 0.502 |
| Location (head/body and tail) |
31/14 | 9/16 | 5/15 | 0.525 |
| Tumor size (mm) * | 37.0 (20.0–100.0) | 33.0 (20.0–100.0) | 38.5 (24.0–74.0) | 0.134 |
| Duodenal invasion (yes/no) | 11/34 | 3/22 | 8/12 | 0.041 |
| Biliary drainage (yes/no) | 15/30 | 9/16 | 6/14 | 0.757 |
| CA19-9 (U/mL) * | 372.0 (<2.0–13, 856.0) | 372 (<2.0–13, 856.0) | 464 (<2.0–13, 292.0) | 0.404 |
| CEA (ng/mL) * | 3.2 (0.8–103.3) | 2.9 (0.8–103.3) | 4.35 (1.5–100.4) | 0.17 |
| Follow-up period (months) * | 25.5 (8.9–48.2) |
CA19-9, carbohydrate antigen 19-9; CA125, cancer antigen 125; CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Performance Status; UR-LAPC, unresectable locally advanced pancreatic cancer. The CRT group (n = 25) included patients who underwent chemoradiotherapy following induction chemotherapy with gemcitabine plus nab-paclitaxel. The CTx group (n = 20) included patients who underwent systemic chemotherapy alone. * Statistical significance at p < 0.05.